LONDON, June 20, 2017 /PRNewswire/ -- Highlights
Download the full report: https://www.reportbuyer.com/product/4946503/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
- The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc.
- Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market.
- Introduction of novel drugs and their cheaper biosimilar formulations with enhanced efficacy and cost-effectiveness is also expected to serve this industry with lucrative opportunities.
- Companies are involved in extensive R&D initiatives for development of innovative molecules and discovering new therapeutic areas for existing drugs.
Advertisement
Download the full report: https://www.reportbuyer.com/product/4946503/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/erythropoietin-epo-drugs-market-is-expected-to-reach-usd-174-billion-by-2025-300477084.html
SOURCE ReportBuyer